CDSCO panel nod to Novartis Ruxolitinib for acute and chronic graft versus host disease

Published On 2022-07-24 08:45 GMT   |   Update On 2022-07-24 08:45 GMT
Advertisement

In response to the pharma major Novartis proposal for additional indication of Ruxolitinib Tablets 5/10/15/20 mg, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has granted permission for additional indication of Ruxolitinib for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies.

Advertisement
This nod is subjected to condition that the firm should submit safety and efficacy data of ongoing Global study and Post Marketing data related to said indication within one year from the approval for evaluation by the committee for its continued marketing.

For more details, check out the full story on the link below:

Novartis Ruxolitinib Gets CDSCO Panel Okay For Acute And Chronic Graft Versus Host Disease


Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News